Glenmark Q1 FY27 results: revenue up 23%, PAT jumps 10x on consol basis
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts less than Nifty Midcap 150 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q1 FY27 results (quarter ended June 30, 2026). Consolidated revenue rose 23% to Rs 40,185 mn from Rs 32,644 mn YoY. Consolidated PAT surged to Rs 4,828 mn vs Rs 470 mn. Standalone PAT was Rs 7,356 mn vs Rs 3,302 mn, boosted by a Rs 2,230 mn exceptional gain from Nebulizer brand transfer to subsidiary. Standalone net sales grew 7.5% to Rs 23,425 mn. Auditor gave unmodified review. Dividend record date Aug 31, AGM Sep 11, 2026.
Strong quarter with consolidated revenue up 23% and PAT nearly 10x. Standalone lifted by exceptional gain. Watch dividend record date Aug 31.